AstraZeneca Plc $AZN Stock Holdings Raised by Sanders Capital LLC

Sanders Capital LLC increased its holdings in AstraZeneca Plc (NYSE:AZN) by 0.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 6,989,827 shares of the company’s stock after buying an additional 2,997 shares during the period. Sanders Capital LLC owned 0.45% of AstraZeneca worth $1,128,647,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Mascoma Wealth Management LLC purchased a new stake in AstraZeneca in the 1st quarter worth approximately $26,000. Roxbury Financial LLC purchased a new position in shares of AstraZeneca during the 2nd quarter valued at $29,000. Resources Management Corp CT ADV bought a new position in shares of AstraZeneca in the first quarter worth $35,000. Allied Private Wealth LLC bought a new position in shares of AstraZeneca in the second quarter worth $35,000. Finally, Laurel Wealth Advisors LLC purchased a new stake in shares of AstraZeneca in the third quarter worth $30,000. 20.35% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Wall Street Zen raised AstraZeneca from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. Weiss Ratings upgraded shares of AstraZeneca from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, October 26th. CICC Research started coverage on shares of AstraZeneca in a report on Sunday, August 23rd. They issued an “outperform” rating and a $198.00 price objective for the company. Royal Bank Of Canada started coverage on shares of AstraZeneca in a report on Tuesday, September 8th. They issued an “outperform” rating on the stock. Finally, Citigroup reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Tuesday, October 6th. Sixteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $206.67.

AstraZeneca Price Performance

NYSE AZN traded down $0.23 during trading hours on Friday, reaching $186.62. The company’s stock had a trading volume of 2,846,843 shares, compared to its average volume of 3,117,912. The firm’s 50-day moving average price is $166.48 and its 200-day moving average price is $180.22. The company has a quick ratio of 0.67, a current ratio of 1.01 and a debt-to-equity ratio of 0.51. AstraZeneca Plc has a 1 year low of $153.41 and a 1 year high of $212.71. The company has a market capitalization of $289.43 billion, a price-to-earnings ratio of 26.40, a PEG ratio of 1.45 and a beta of 0.24.

AstraZeneca (NYSE:AZN) last released its quarterly earnings data on Friday, October 30th. The company reported $2.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.60 by $0.19. AstraZeneca had a net margin of 17.68% and a return on equity of 31.85%. The firm had revenue of $16.21 billion for the quarter, compared to analysts’ expectations of $16 billion. During the same quarter last year, the business posted $2.38 earnings per share. The company’s revenue for the quarter was up 6.5% compared to the same quarter last year. On average, equities research analysts predict that AstraZeneca Plc will post 10.22 EPS for the current fiscal year.

AstraZeneca Company Profile

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries.

AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.